Influence of Smoking Cessation or Switching to THS on Disease Activity in IBD Patients.

NCT05196282 | Unknown

• 1 other identifier: HW-001-DE
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The main goal of this study is to evaluate the effects of smoking cessation or switching from cigarette smoking to THS (tobacco heat system) on the clinical course of UC (ulcerative colitis) and CD (Crohn´s disease) in adult smokers who were diagnosed with IBD and are under treatment. Measures using validated/standardized assessment methods and self-reported outcomes will be assessed in patients who stop smoking or switch from smoking to using THS over the investigational period of 6 months, relative to smokers who continue smoking cigarettes.

Conditions

Smoking in IBD Patients

Outcome Measures

Primary Outcomes (2)

• Activity Scores

  partial Mayo Score, Range from 0-9. The higher the more active

  6.5 months

• Activity Scores

  CDAI, Crohn's disease activity index - Range from 0-600. The higher the more active

  6.5 months

Study Arms (6)

UC, Smoker

Other: Smoking cessation

UC, Smoking cessation

Other: Smoking cessation

UC, THS user

Other: Smoking cessation

CD, Smoker

Other: Smoking cessation

CD, Smoking cessation

Other: Smoking cessation

CD, THS user

Other: Smoking cessation

Interventions

Smoking cessation OTHER

Patients are forced to stop smoking

CD, Smoker; CD, Smoking cessation; CD, THS user; UC, Smoker; UC, Smoking cessation; UC, THS user

Eligibility Criteria

• Age: 19 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Smoking IBD patients under treatment

You may qualify if:

• For all patients:
• Patient has signed the ICF (Informed Consent Form) and is able to understand the information provided in the ICF. Patient can sign or not the optional ICF on long-term biobanking of samples.
• years ≤ patient's age ≤ 75 years old
• Patients who were diagnosed with UC or CD.
• Patient's disease activity is mild to moderate (PMS ≤ 6; CDAI: ≤ 300) and has not changed for at least the last 3 months, as judged by the Investigator. a
• Patient is ready to comply with the study procedures (including readiness to accept smoking abstinence and/or use of THS).
• Patient has smoked at least 5 commercially available and/or "roll your own cigarette" every day (no cigarette brand restriction) for at least the last 1 year, based on self-reporting. Smoking status will be verified based on a urinary cotinine test (i.e., cotinine ≥ 200 ng/mL). Specific to patients who prefer to continue using nicotine-containing and tobacco product after having been advised to quit smoking:
• Not intending to quit using THS or smoking cigarettes within the next 6 months (to be checked at V2). Specific to patients who prefer to stop smoking cigarettes:
• Any patient who is willing to attempt quitting cigarette smoking

You may not qualify if:

• For all patients:
• Patients with severe disease activity (PMS \> 5; CDAI \> 300), as judged by the Investigator.
• Female patients who are pregnant or breast-feeding
• Female patients who are planning to become pregnant during the next 8 months
• Patients with a history of recent and current alcohol and substance abuse
• Patient is ineligible as judged by the Investigator to participate in the study for any reason (e.g., medical, psychiatric and/or social reason), including any abnormal safety laboratory values obtained at screening that are judged as clinically significant by the investigator.
• Patient is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners, or patients who are involuntarily incarcerated).
• Patient with any major illness/condition or evidence of an unstable clinical condition (e. g. renal, hepatic, hematologic, gastrointestinal \[except the disease under study\], endocrine, cardiovascular, pulmonary, immunologic, or local active infection/infectious illness) that, in the investigator's judgment, could impact study results.
• The patient has colorectal carcinoma or high-grade dysplasia adenoma.
• As per the investigator's judgment, the patient has medical conditions which require or will require in the course of the study, a medical intervention (e. g. start of treatment, surgery, hospitalization), which may interfere with the study participation and/or study results.
• Any other clinically significant medical condition, which as per the judgment of the PI would jeopardize the safety of the patient.
• Clinically significant ECG alterations that will not allow patient to participate in the study, per Investigator's discretion

Sponsors & Collaborators

• HaFCED e.K.: lead

Central Study Contacts

Stefanie Howaldt, MD

CONTACT

+4940423265151; Howaldt@hafced.de

Ekaterini Saroglou, Dipl. oec. troph.

CONTACT

+4940423265151; Saroglou@hafced.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2022
• First Posted: January 19, 2022
• Study Start: January 15, 2022
• Primary Completion: January 15, 2023
• Study Completion: January 15, 2023
• Last Updated: January 19, 2022

Record last verified: 2022-01